Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Dissect the impact, safety and effectiveness of gene therapy at the whole organismal level by cell-free DNA signatures

Project description

Examining cell-free DNA signatures to improve diagnostics

Gene therapy (GT) using integrative vectors holds promise for treating various disorders, but patient responses vary. The success of GT depends on the integration of engineered cells into tissues and individual patient-specific factors. The ERC-funded TalesfromDeath project will investigate cell-free DNA (cfDNA) signatures in patients who have undergone GT. Through non-invasive studies, it will track changes associated with disease progression and treatment while identifying integration sites on cfDNA to assess the activity of engineered cells in peripheral organs. Focusing on patients treated with haematopoietic stem cell GT for inherited metabolic disorders and engineered T-cells for tumours, the project’s findings could enhance diagnostics, help identify suitable GT candidates, and provide early insights into treatment efficacy and toxicity.

Objective

Gene therapy (GT) with integrative vectors has emerged as a revolutionary intervention for the treatment of inherited and acquired disorders. Despite the great achievements, a major challenge pertains to the heterogeneity of responses that can be obtained in patients. The success of these applications critically depends on the ability of engineered cells to functionally integrate within the patients’ tissues to re-establish the physiological functions. Intrinsic features of the cellular drug product, and inter-individual factors present at the time or after cell infusion may modulate the clinical outcome.
The proposed investigation aims at characterizing cell-free (cfDNA) signatures in patients who underwent GT. Epigenetic studies on cfDNA will capture the organism-wide changes induced by disease progression and consequent to the treatment in a non-invasive fashion. Furthermore, the retrieval of integration sites on cfDNA will provide molecular insights into the activity, clonality and persistence of engineered cells in peripheral organs. The translational relevance of this proposal will be directly assessed in unique clinical settings represented by patients treated with hematopoietic stem cell GT for the correction of inherited metabolic disorders, and with engineered T-cells to fight hematological and solid tumors. By correlating patient-derived cfDNA signatures with clinical variables outcomes, I will establish if these analyses can predict the impact of engineered cells at the whole organismal level potentially highlighting mechanisms of therapeutic success and failure that have not yet been explored. The advanced knowledge gained with this project may prompt a more accurate diagnosis evaluation, assist in selecting patients who will benefit from GT, and provide early insights on the efficacy and toxicity of cellular therapies guiding for a more personalized therapeutic intervention to reduce inter-individual variability.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC - HORIZON ERC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2024-COG

See all projects funded under this call

Host institution

OSPEDALE SAN RAFFAELE SRL
Net EU contribution
€ 2 000 000,00
Address
VIA OLGETTINA 60
20132 Milano
Italy
Region
Nord-Ovest Lombardia Milano
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 2 000 000,00

Beneficiaries (1)